ASX-LISTED cannabis company Zelda has announced an expansion of its pre-clinical pancreatic cancer research collaboration with Curtin University.
It will now include in vivo animal model studies that will be pivotal to facilitating future human clinical trials, the company said, with study protocols mirroring human treatment protocols.
The above article was sent to subscribers in Pharmacy Daily's issue from 07 Mar 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 07 Mar 18
